Table 4.
CYP2A6 genotypes-predicted metabolizer status in relation to the risk of developing lung cancer, The Singapore Chinese Health Study 1993–2014
| CYP2A6 activity | Median NMR among controls | Cases/controls | OR (95% CI)a | OR (95% CI)b |
|---|---|---|---|---|
| CYP2A6 genotype-predicted | ||||
| Normal | 1.60 | 35/19 | 1.00 | 1.00 |
| Intermediate | 1.40 | 60/40 | 0.81 (0.40–1.64) | 0.85 (0.41–1.77) |
| Slow | 0.99 | 74/79 | 0.47 (0.25–0.91) | 0.55 (0.28–1.08) |
| Poor | 0.41 | 28/59 | 0.23 (0.11–0.49) | 0.32 (0.15–0.70) |
| P for trend | <0.001 | <0.001 | ||
| NMR | ||||
| 4th quartile | 2.00 | 59/49 | 1.00 | 1.00 |
| 3rd quartile | 1.17 | 61/49 | 1.03 (0.60–1.76) | 1.09 (0.62–1.91) |
| 2nd quartile | 0.73 | 48/49 | 0.77 (0.44–1.36) | 0.86 (0.48–1.54) |
| 1st quartile | 0.37 | 29/50 | 0.45 (0.24–0.83) | 0.62 (0.32–1.18) |
| P for trend | 0.010 | 0.132 | ||
CI, confidence interval; NMR, nicotine metabolite ratio; OR, odds ratio.
aOdds ratios were calculated using unconditional logistic regression models with adjustment for matching factors including age, gender, year of enrollment, and dialect group.
bIn addition to matching factors, odds ratios were adjusted for cigarettes per day, years of smoking and urinary total nicotine equivalents.